Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …
disease and are at very high risk of developing early-onset dementia, which is now the …
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
F Gonzalez-Ortiz, M Turton, PR Kac, D Smirnov… - Brain, 2023 - academic.oup.com
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
J Arranz, N Zhu, S Rubio-Guerra… - Alzheimer's Research & …, 2024 - Springer
Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear …
Objectives This longitudinal study compared emerging plasma biomarkers for
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
Plasma biomarkers for neurodegenerative disorders: ready for prime time?
Plasma biomarkers for neurodegenerative disorders: ready for... : Current Opinion in
Psychiatry Plasma biomarkers for neurodegenerative disorders: ready for prime time …
Psychiatry Plasma biomarkers for neurodegenerative disorders: ready for prime time …
Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease
Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
Overview of the blood biomarkers in Alzheimer's disease: promises and challenges
The increasing number of people with advanced Alzheimer's disease (AD) represents a
significant psychological and financial cost to the world population. Accurate detection of the …
significant psychological and financial cost to the world population. Accurate detection of the …
The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
Abstract Background Cerebrospinal fluid (CSF) Aβ1–42 levels and the Aβ1–42/Aβ1–40 ratio
are markers of amyloid pathology, but previous studies suggest that their levels might be …
are markers of amyloid pathology, but previous studies suggest that their levels might be …